The Gustatory Signaling Pathway and Bitter Taste Receptors Affect the Development of Obesity and Adipocyte Metabolism in Mice by Avau, Bert et al.
RESEARCH ARTICLE
The Gustatory Signaling Pathway and Bitter
Taste Receptors Affect the Development of
Obesity and Adipocyte Metabolism in Mice
Bert Avau1, Dries Bauters2, Sandra Steensels1, Laurien Vancleef1, Jorien Laermans1,
Jens Lesuisse3, Johan Buyse3, H. Roger Lijnen2, Jan Tack1, Inge Depoortere1*
1 Translational Research Center for Gastrointestinal Disorders, Gut Peptide Research Lab, University of
Leuven, Gasthuisberg O&N1, box 701, 3000 Leuven, Belgium, 2 Center for Molecular and Vascular Biology,
University of Leuven, Gasthuisberg O&N1, box 911, 3000 Leuven, Belgium, 3 Laboratory of Livestock




Intestinal chemosensory signaling pathways involving the gustatory G-protein, gustducin,
and bitter taste receptors (TAS2R) have been implicated in gut hormone release. Alterations
in gut hormone profiles may contribute to the success of bariatric surgery. This study investi-
gated the involvement of the gustatory signaling pathway in the development of diet-induced
obesity and the therapeutic potential of targeting TAS2Rs to induce body weight loss. α-gust-
ducin-deficient (α-gust-/-) mice became less obese than wild type (WT) mice when fed a high-
fat diet (HFD). White adipose tissue (WAT) mass was lower in α-gust-/- mice due to increased
heat production as a result of increases in brown adipose tissue (BAT) thermogenic activity,
involving increased protein expression of uncoupling protein 1. Intra-gastric treatment of
obeseWT and α-gust-/- mice with the bitter agonists denatonium benzoate (DB) or quinine
(Q) during 4 weeks resulted in an α-gustducin-dependent decrease in body weight gain asso-
ciated with a decrease in food intake (DB), but not involving major changes in gut peptide
release. BothWAT and 3T3-F442A pre-adipocytes express TAS2Rs. Treatment of pre-adipo-
cytes with DB or Q decreased differentiation into mature adipocytes. In conclusion, interfering
with the gustatory signaling pathway protects against the development of HFD-induced obe-
sity presumably through promoting BAT activity. Intra-gastric bitter treatment inhibits weight
gain, possibly by directly affecting adipocyte metabolism.
Introduction
Obesity is one of the major healthcare problems, affecting millions of people worldwide [1].
Treatment options include life-style changes and pharmacological treatment, but the outcomes
are often disappointing and only few drugs can be used on a long-term basis [2]. Therefore,
bariatric surgery provides a powerful alternative, resulting in a sustained weight loss and often
also remission of comorbidities, such as type 2 diabetes [3]. However, this is an invasive
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technique, only applied in morbidly obese patients. Thus, there is a need for alternative treat-
ment options.
The gut responds to ingested nutrients through alterations in gastrointestinal motility and
the release of gut peptides that help to regulate digestion and absorption but also induce satia-
tion [4]. The drastic changes in body weight observed after bariatric surgery are accompanied
by an equally drastic restoration of postprandial gut peptide release, including glucagon-like
peptide 1 (GLP-1), peptide YY (PYY) and, although less consistent, ghrelin [5], all dysregulated
in obese patients [6, 7]. Therefore, influencing the release of gut peptides might provide a phar-
macological alternative to bariatric surgery. The chemosensory pathways involved in the regu-
lation of nutrient-induced gut peptide release have remained elusive for a long time. The
discovery of taste receptors and their downstream signaling pathways, including the gustatory
G-protein gustducin, on endocrine cells in the gut suggests that they might sense nutrients,
much like they do in taste receptor cells on the tongue, to regulate gut peptide release [8, 9].
Indeed, the release of the anorexigenic gut peptides cholecystokinin (CCK) and GLP-1 is regu-
lated by activation of sweet, umami, fatty acid and bitter taste receptors [8–13]. Also the hunger
hormone ghrelin is colocalized with the gustatory G-protein subunits, α-gustducin and α-
transducin, and with sweet taste and fatty acid taste receptors in the mouse stomach [14–16].
Moreover, intra-gastric administration of bitter agonists induced an α-gustducin-dependent
increase in plasma ghrelin levels, accompanied by a short-term increase in food intake [14].
This was however followed by a longer lasting decrease in food intake, correlating with an inhi-
bition of gastric emptying. Vegezzi et al. have shown that bitter taste receptors and α-gustducin
are differentially expressed in the gastrointestinal tract in response to a high-fat diet in mice
[17]. The expression of stomach taste signaling elements has also been reported to be altered in
obese patients, with a decreased expression of the sweet/umami taste receptor TAS1R3, but an
increased expression of the fatty acid receptor FFAR4 (GPR120), α-gustducin, PLCβ2 and
TRPM5 [18].
These findings suggest that nutrient sensing via the taste signaling pathway may be altered
during nutrient excess. To test this hypothesis, we investigated whether the development of
obesity was influenced in mice deficient in the α-subunit of the gustatory G-protein gustducin
(α-gust-/-) and thus in the taste signaling pathway. Furthermore in view of the inhibitory effect
after intra-gastric administration of bitter on food intake in mice [14] and on appetite signaling
in humans [19], we investigated whether prolonged intra-gastric administration of bitter ago-
nists influences food intake and hence body weight in high-fat diet induced obese wild type
(WT) mice, but not in obese α-gust-/- mice.
Materials and Methods
Animals
Wild type C57BL/6 (Janvier) and α-gust-/- (kindly provided by R. Margolskee, Monell Chemi-
cal Senses Center, Philadelphia) were kept in the animal facility (2 mice per cage) in a 14–10
light-dark cycle with ad libitum access to chow and water. All animal experiments were
approved of by and carried out in accordance to the guidelines of Ethical Committee for Labo-
ratory Experimentation (ECD) of the University of Leuven (project: P028/2014). All efforts
were made to minimize animal suffering.
Experimental design
The animals (n = 12–16 per group) were placed after weaning on a high fat diet (60% kcal fat,
D12492, Research Diets) for 15 weeks. After becoming diet-induced obese, the animals were
treated once daily, 1 hour prior to lights off, by intra-gastric gavage with either denatonium
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benzoate (60 μmol/kg, Sigma-Aldrich) or quinine-HCl (160 μmol/kg, Fagron) or water as con-
trol, during 4 weeks. At the day of sacrifice, the animals were fasted for 6 hours, before receiv-
ing a test meal (Nutridrink1, Nutricia) by gavage. The animals were anaesthetized with a
mixture of xylazine and ketamine, 10 min after receiving the test meal, and sacrificed by cardiac
exsanguination and decapitation. Blood samples were supplemented with 1 mM EDTA, 4 mM
AEBSF (Sigma-Aldrich) and dipeptidyl peptidase 4 inhibitor (10 μl/ml, Millipore) and were
centrifuged. Plasma samples and relevant tissues were collected and stored appropriately for
further analysis. The hypothalamus was dissected as a whole using a mouse brain matrix (Zivic
instruments).
Respiratory Quotient and Heat production measurements
Mice were kept in their original cages during the measurements. Gas exchanges were measured
in an open circuit indirect calorimetric unit after an adaptation period of 3 days, for 7 consecu-
tive days, as described previously [20]. The respiratory units consisted of three light and tem-
perature controlled climatic chambers, each containing two respiratory cells, a gas analyzer
unit and a data acquisition system. The paramagnetic O2 analyzer (ADC O2-823A) and infra-
red CO2 analyzer ADC D⁄8U⁄54⁄A) were calibrated before each measurement using gas stan-
dards. O2 and CO2 concentrations from air samples coming out of each cell were measured for
60 s every 15 min over 24 h. The CO2 production and O2 consumption were calculated from
the differences between the gas concentrations of the fresh outside air and the outlet air of each
cell. The respiratory quotient was calculated as the ratio of the volume of CO2 produced to the
volume of O2 consumed. Heat production was calculated according to the formula of Romijn
and Lokhorst[21]: heat production (kJ/h) = 16.18 O2 (l/h) + 5.02 CO2 (l/h).
Quantitative Real-time PCR (qRT-PCR)
Tissues were stabilized in RNA later (Qiagen), total RNA was isolated using the RNeasy mini
kit (Qiagen), and treated with the Turbo DNA-free kit (Ambion, Life technologies) to exclude
contamination of genomic DNA before reverse transcription using Superscript II Reverse
Transcriptase (Invitrogen, Life technologies). The qRT-PCR reaction was performed as
described previously, using the Lightcycler 480 (Roche Diagnostics) with the Lightcycler 480
Sybr Green I Master mix (Roche Diagnostics), [22] and analyzed according to the method of
Vandesompele et al. [23]. Results were expressed relative to the geometric mean of the normal-
ized expression of the three most stable housekeeping genes tested; glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), ribosomal protein L13a (RPL13a) and β-actin. The primers used are
summarized in S1 Table.
Radioimmunoassay for octanoyl and total ghrelin
Plasma samples were acidified (10%) with 1 N HCl, immediately after collection. After extrac-
tion on a Sep-Pak C18 cartridge (Waters Corporation), samples were dried in a speedvac and
the radioimmunoassay was performed as described previously [14].
Enzyme-linked immunosorbent assay (ELISA) for GLP-1 and Leptin/
Insulin
Plasma samples were analyzed for GLP-1 using the active GLP-1 (ver. 2) Kit and for leptin and
insulin using the mouse metabolic kit (MesoScale Discovery), according to the manufacturer’s
instructions.
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Quantitative adipocyte histology
Adipocyte size was measured on haematoxylin and eosin stained sections of fixated and paraf-
fin embedded gonadal adipose tissue (10 μm) with the Image J open source analysis software.
For each tissue, 8 random views on 4 sections were selected and analyzed.
Western blotting for UCP1
Total protein fromWT and α-gust-/- mice adipose tissue was separated using SDS-PAGE and
loaded onto a PVDF membrane. The membrane was incubated overnight at 4°C with the pri-
mary antibodies: rabbit anti-UCP1 (1:2000, Sigma-Aldrich U6382) and rabbit anti-α-tubulin
(1:1000, Thermo Fisher Scientific PA5-22060) as a protein loading control. The secondary anti-
body used was peroxidase conjugated goat anti-rabbit (1:2000, Dako P0488) (1h, RT). Bands
were quantified using relative densitometry and normalized to α-tubulin, using Imagelab 4.0
(Bio-Rad).
3T3-F442A differentiation assay
Murine 3T3-F442A pre-adipocytes [24] were grown in basal medium at sub-confluence. Dif-
ferentiation was induced as described previously [25]. During differentiation, the medium was
supplemented with 150 μMDB, 100 μM quinine or vehicle. At regular time points, cell lysates
were taken for RNA extraction and the extent of differentiation was quantified from Oil Red
O-uptake by lipid containing cells [25]. Data presented are mean of 6–8 observations per
condition.
Statistical analysis
Results are presented as means±SEM. Changes in body weight, food intake, respiratory quo-
tient and heat production over time between different genotypes and treatments were analyzed
using a repeated measures mixed models analysis (SAS software package 9). Other data that
did not involve multiple measurements over time were analyzed with a one-way ANOVA
(3T3-F442A cells) or 2-way ANOVA (mice), followed by planned comparisons post-hoc test-
ing, corrected for multiple testing with the Bonferroni correction (Statistica 12, Statsoft). Signif-
icance was accepted at the 5% level.
Results
α-gustducin is involved in the induction of obesity during a high-fat diet
WT and α-gust-/- mice were put on a high fat diet (HFD) after weaning. Although their initial
body weight did not differ, body weight gain started to diverge at week 4 (Fig 1A). Compared to
WTmice, body weight of α-gust-/- mice was 9% lower (WT: 49±0.6 g vs α-gust-/-: 44.8±0.7 g,
P<0.001) after 19 weeks on a HFD. This indicates that the gustatory G-protein subunit α-gust-
ducin is involved in the induction of body weight gain during a HFD.
Energy intake was measured during the last 4 weeks before sacrifice. Despite their lower body
weight, α-gust-/- mice consumed significantly more chow thanWTmice (P<0.05) (Fig 1B). The
mRNA expression of the orexigenic hypothalamic neuropeptide, neuropeptide Y (NPY; P>0.05)
was unchanged, while the expression of agouti-related peptide (AgRP; P = 0.06) tended to be
higher in the hypothalamus of α-gust-/- mice compared toWTmice (Fig 1C). On the other hand,
the hypothalamic mRNA expression of the anorexigenic neuropeptide pro-opiomelanocortin
(POMC) was significantly (P<0.05) elevated in α-gust-/- mice (Fig 1D). There were no differ-
ences between genotypes in postprandial plasma ghrelin levels (octanoyl ghrelinWT: 15.4±0.8
pg/ml vs α-gust-/-:17.5±1.6 pg/ml; total ghrelinWT: 328±10 pg/ml vs α-gust-/-: 330±7 pg/ml)
α-Gustducin and TAS2Rs in Obesity
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and active GLP-1 levels (WT: 0.36±0.1 pg/ml vs α-gust-/-:0.44±0.06 pg/ml). Also plasma levels of
glucose (WT: 311±8 mg/dl vs α-gust-/- 310±10 mg/dl) and insulin (WT: 2774±299 pg/ml vs α-
gust-/-: 2427±222 pg/ml) did not differ significantly between genotypes.
After 17 weeks on a HFD, mice were placed for one week in respiratory cells, to measure O2
consumption and CO2 production. The respiratory quotient did not differ between WT and α-
gust-/- mice, indicating no difference in their preference for the substrate used for energy pro-
duction (Fig 1E). However, the total heat production was significantly higher in α-gust-/- mice
compared to WT mice (P<0.05) (Fig 1F).
After 19 weeks on a HFD, mice were sacrificed and different depots of white adipose tissue
(WAT) were collected. The sum of the gonadal, subcutaneous and mesenteric fat mass of α-
gust-/- mice was 15% lower (P<0.01) compared to that of WT mice (Fig 2A). This difference
was mainly driven by differences in gonadal (P = 0.05) and subcutaneous (P<0.05), and to a
lesser extent in mesenteric WAT mass (P>0.05). Hematoxylin and eosin stained sections from
gonadal WAT were examined histologically. Adipocytes from α-gust-/- mice were significantly
smaller compared to adipocytes fromWTmice (WT: 6093±71 μm2 vs α-gust-/-:4913±162 μm2;
P<0.01). Correspondingly, plasma leptin was significantly lower (P<0.001) in α-gust-/- mice,
compared to WT mice (Fig 2B).
The weight of intrascapular brown adipose tissue (BAT) did not differ between genotypes
(WT: 290±14 mg, α-gust-/-: 253±22 mg). Given the observed difference in heat production, we
determined the mRNA expression of uncoupling protein 1 (UCP1), the hallmark of brown adi-
pocytes, in WAT depots of WT and α-gust-/- mice. This was increased in gonadal (P<0.001)
and subcutaneous (P = 0.06), but not in mesenteric fat depots of α-gust-/- mice compared to
WT mice (Fig 2C–2E). However, at the protein level, this increase in UCP1 expression could
not be confirmed in subcutaneous WAT. In addition, also the mRNA expression of other
brown adipocyte markers, PR domain containing 16 (PRDM16) and peroxisome proliferator-
activated receptor γ coactivator 1 α (PGC1α), was not changed in subcutaneous WAT (S1 Fig).
On the other hand, the protein expression of UCP1 was increased 2.4 fold in the intrascapular
BAT of α-gust-/- mice (Fig 2F).
Treatment of obese mice with bitter agonists inhibits body weight gain in
an α-gustducin-dependent fashion
After 15 weeks on a HFD, mice were gavaged daily for 4 weeks with bitter agonists (denato-
nium benzoate (DB) or quinine (Q)) or water. WT, but not α-gust-/- mice, treated with DB
(treatment x genotype, P<0.01) or quinine (treatment x genotype, P<0.01) lost body weight
compared to water-treated mice (Fig 3A and 3B). Quinine was significantly more potent in
inducing weight loss in WT mice than DB (P<0.01). In α-gust-/- mice, quinine was without
effect but DB even significantly increased body weight (P<0.01). Correspondingly, the com-
bined weight of gonadal, subcutaneous and mesenteric fat was lower in DB (P<0.01) or Q
(P = 0.06) treated compared to water-treated WTmice, but not in α-gust-/- mice (Fig 3C, S2
Table). Gonadal WAT was selected for further histological analysis. Both DB and quinine treat-
ment induced a decrease in adipocyte size, with a significant treatment x genotype effect
(P<0.05) for DB but not for quinine (S2 Fig). UCP1 mRNA levels in WAT were not changed
Fig 1. Comparison of the energy balance betweenWT and α-gust-/- mice on a high fat diet. (a) Time course of body weight of WT (n = 16) and α-gust-/-
(n = 16) mice, on a high-fat diet for 19 weeks post-weaning. (b) Energy intake (kcal/day) of WT (n = 16) and α-gust-/- (n = 16) mice during the last 4 weeks
before sacrifice. (c-d) Relative hypothalamic AgRP and POMCmRNA levels in WT (n = 10) and α-gust-/- (n = 9) mice after 19 weeks on a HFD. (e-f)
Respiratory quotient and heat production, measured continuously during 1 week in WT (n = 8) and α-gust-/- (n = 8) mice. *: P<0.05; **: P<0.01, ***: P<0.001
WT vs α-gust-/-.
doi:10.1371/journal.pone.0145538.g001
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Fig 2. Difference in adiposity between high-fat diet (19 weeks) induced obeseWT and α-gust-/- mice. (a) The sum of gonadal, subcutaneous and
mesenteric white adipose tissue mass as percentage of total body weight in WT (n = 16) and α-gust-/- mice (n = 16). (b) Plasma leptin levels in WT (n = 10)
and α-gust-/- mice (n = 11). (c-e) Relative gonadal, subcutaneous and mesenteric fat UCP1 mRNA levels in WT (n = 6–9) and α-gust-/- mice (n = 6–9). (f)
α-Gustducin and TAS2Rs in Obesity
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by treatment with DB or quinine, as illustrated for gonadal WAT in both genotypes (Fig 3D).
Bitter treatment did not influence the weight of other organs, such as liver, kidneys, heart and
intrascapular brown adipose tissue (S2 Table). In addition, plasma levels of the toxicity markers
aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase were
measured, and were not changed, apart from a small increase in ALT in quinine treated WT
mice (S3 Fig).
DB-treatment decreased energy intake in WT, but not in α-gust-/- mice, compared to water-
treated mice (treatment x genotype, P<0.05) (Fig 3E and 3F). This difference was mainly
driven by a decreased energy intake in the first week of the treatment (treatment x genotype,
P<0.05). Quinine treatment did not affect energy intake. Correspondingly, the hypothalamic
mRNA expression of AgRP (treatment x genotype, P<0.05) and NPY (treatment x genotype,
P<0.01) was lower in DB treated WT, but not in DB treated α-gust-/- mice compared to the
water-treated animals (Fig 4A and 4B). The mRNA expression of POMC did not differ between
treatments (Fig 4C). Quinine had no effect on hypothalamic mRNA expression in WT mice.
Bitter treatment had no major influence on respiratory quotient or heat production, during the
light as well as during the dark phase (S4 Fig).
Treatment of obese mice with bitter agonists has minor effects on
plasma gut hormone levels
Plasma octanoyl and total ghrelin levels measured 15 min after intra-gastric administration of
a test meal (Nutridrink1) did not differ between treatments or genotypes (Fig 5A and 5B). In
contrast, meal-induced plasma levels of active GLP-1 (7-36amide and 7–37) were significantly
increased in DB (P<0.05), but not quinine treated animals in a genotype independent manner
(Fig 5C). Bitter treatment did not affect plasma insulin or glucose levels in both genotypes (Fig
5D and S5 Fig).
Bitter agonists inhibit the differentiation of 3T3-F442A pre-adipocytes
into mature adipocytes
To study a possible direct effect of bitter agonists on adipose tissue, the expression of a selection
of bitter taste receptors known to be activated by DB or quinine and their associated G-protein
α-gustducin was studied in WAT. mRNA expression for mTas2R108 (DB and quinine),
mTas2R135 (DB) and α-gustducin was demonstrated in gonadal, subcutaneous and mesenteric
fat of WT mice (S6 Fig). The same TAS2Rs and α-gustducin were also expressed in 3T3-F442A
pre-adipocytes (S6 Fig). To study whether bitter agonists could directly affect adipocyte differ-
entiation, 3T3-F442A pre-adipocytes were stimulated to form mature adipocytes in the pres-
ence or absence of DB (150 μM) or quinine (100 μM). Cells treated with DB or quinine showed
a decreased lipid accumulation, visualized by Oil-Red O staining during differentiation (Fig
6A). DB (P<0.01) and quinine (P<0.01) significantly inhibited lipid accumulation both at day
6, halfway the differentiation protocol, and at day 12 (DB: P<0.01, Q: P<0.001), after full dif-
ferentiation (Fig 6B). At the gene expression level, mRNA expression for the differentiation
markers leptin (Fig 6C), adiponectin (Fig 6D), peroxisome proliferator-activated receptor γ
(PPARγ), adipocyte protein 2 (AP-2), fatty acid synthase (FAS) and uncoupling protein 2
(UCP2), but not pre-adipocyte factor-1 (Pref-1) was inhibited after bitter treatment (Table 1).
Neither of the treatments was toxic to the cells, as verified by a trypan blue staining (Fig 6E).
Relative intrascapular brown adipose tissue UCP1 protein level expression in WT (n = 4) and α-gust-/- mice (n = 4) as determined byWestern blot. *: P<0.05,
**: P<0.01, ***: P<0.001WT vs α-gust-/-.
doi:10.1371/journal.pone.0145538.g002
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Fig 3. Comparison of the energy balance during treatment with bitter agonists of obeseWT and α-gust-/- mice. (a-b) Changes in body weight during
daily intra-gastric administration of water, DB (60 μmol/kg) or Q (160 μmol/kg) for 4 weeks in high-fat diet (15 weeks) obese (a) WT (n = 9–12) and (b) α-gust-/-
mice (n = 8–12). Results are expressed as percentage change from baseline, defined as the mean body weight measured during one week before the
treatment. (c) Combined weight of gonadal, subcutaneous and mesenteric fat pads as percentage of total body weight of control or bitter treated WT
(n = 9–12) and α-gust-/- mice (n = 9–12), at sacrifice. (d) Relative mRNA expression of UCP1 in gonadal WAT of control or bitter treatedWT (n = 7–9) and α-
α-Gustducin and TAS2Rs in Obesity
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To test whether the effects of DB and Q were mainly on adipocyte differentiation or rather on
metabolism, 3T3-F442A cells were treated either only during the first 4 days of differentiation
or alternatively only during the last 8 days with DB or Q. Cells that were incubated only during
the first 4 days of differentiation with DB or Q, had no change in lipid uptake at the end of the
differentiation period (O.D. at 490 nm: vehicle 0.51±0.01 vs DB 0.52±0.02 vs Q 0.53±0.02,
P>0.05). However, if cells were treated from day 4 to day 12 of the differentiation period, a sig-
nificant reduction in lipid uptake was noted at the end of the differentiation period in response
to bitter treatment (O.D. at 490 nm: vehicle 0.48±0.01 vs DB 0.38±0.02 vs Q 0.34±0.03, P<
0.01). These data indicate that bitter agonists directly influence adipocyte metabolism rather
than differentiation in vitro.
Discussion
The current study investigated the involvement of the gustatory signaling pathway in the devel-
opment of obesity, by comparing weight gain and food intake in α-gust-/- and WT mice during
a high-fat diet. α-gust-/- mice were protected from developing obesity, possibly due to effects
on BAT activity, demonstrating the crucial role of α-gustducin in weight gain. Moreover, intra-
gastric treatment of these mice with bitter tastants induced weight loss in an α-gustducin-
dependent fashion. These results show that interfering with the taste signaling pathway might
hold promise for the treatment of obesity.
α-gust-/- mice had a less severe obese phenotype than WT mice after 15 weeks on a high-fat
diet as evidenced by their lower body weight, WAT mass and lower plasma levels of leptin.
gust-/- (n = 7–8) mice. (e-f) Changes in energy intake during the 4-week treatment period in (e) WT (n = 6–8) and (f) α-gust-/- mice (n = 7–8), expressed as
percentage change from baseline, defined as the mean energy intake measured during 9 days before the treatment. **: P<0.01; ***: P<0.001 water vs
bitter; ##: P<0.01 treatment (water vs DB) x genotype.
doi:10.1371/journal.pone.0145538.g003
Fig 4. Hypothalamic neuropeptide mRNA expression after treatment with bitter agonists of obeseWT and α-gust-/- mice.Relative hypothalamic
AgRP (a), NPY (b) and POMC (c) mRNA expression levels in HFD-obeseWT (n = 7–10) and α-gust-/- (n = 6–9) mice after 4 weeks of daily gavage with
water, DB or quinine. *: P<0.05 water vs DB or Q; #: P<0.05; ##<0.01 treatment (water vs DB) x genotype.
doi:10.1371/journal.pone.0145538.g004
α-Gustducin and TAS2Rs in Obesity
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Furthermore, heat production was increased in these mice. Interestingly, gonadal and subcuta-
neous fat pads of α-gust-/- mice showed an increased mRNA expression of UCP1, the hallmark
of brown adipose tissue (BAT) [26]. This suggests the induction of browning of white adipose
stores, a concept that has received much attention in recent years as a possible treatment for
obesity [27–29]. Unfortunately this observation could not be confirmed at the protein level.
However, UCP1 protein levels in the BAT of α-gust-/- mice were increased compared to WT
mice. UCP1 is involved in the uncoupling of oxidative phosphorylation from ATP synthesis in
the mitochondria of BAT, leading to the generation of heat, which is crucial in the maintenance
of body temperature. This result indicates that the taste signaling pathway is involved in the
regulation of heat production in BAT. However, the exact location where this regulation occurs
remains uncertain.
It is as yet uncertain which taste stimuli are responsible for the differences between WT and
α-gust-/- mice, since α-gustducin has been shown to couple to sweet, umami, bitter and even
fatty acid receptors [30, 31]. Sweet taste receptors have previously been described on 3T3-L1
pre-adipocytes, and the addition of artificial sweeteners resulted in an inhibited differentiation
to mature adipocytes [32]. The authors however found that this was a Gαs-dependent process.
Fig 5. Meal-induced effects on plasma hormone levels after treatment with bitter agonists of obeseWT and α-gust-/- mice. (a-b) Plasma octanoylated
and total ghrelin levels in control or bitter treatedWT (n = 8–11) and α-gust-/- (n = 8–12) mice. (c) plasma active GLP-1 levels in bitter treatedWT (n = 9–12)
and α-gust-/- mice (n = 10–12). (d) plasma insulin levels in bitter treated WT (n = 6–12) and α-gust-/- (n = 9–12) mice.
doi:10.1371/journal.pone.0145538.g005
α-Gustducin and TAS2Rs in Obesity
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In contrast, Simon et al. reported a TAS1R-independent increase in adipogenesis in 3T3-L1
cells in response to treatment with artificial sweeteners [33]. Nevertheless, mice deficient in
either TAS1R2 or TAS1R3 had a lower body weight compared to WT animals when fed a
Fig 6. Effect of bitter agonists on differentiation of 3T3-F442A preadipocytes. (a) Representative Oil-Red O stained 3T3-F442A cells at day 12 of
differentiation in the presence of vehicle, 150 μMDB or 100 μMQ. (b) Quantification of the Oil-Red O uptake at differentiation day 6 (n = 4) and 12 (n = 8). (c-
d) Relative mRNA expression of the markers leptin and adiponectin during differentiation in the absence and presence of DB or Q (n = 6). (e) Trypan blue cell
viability assay, presented as the amount of dead cells (% cells stained) after the 12-day differentiation period in the absence and presence of DB or Q (n = 3).
**: P<0.01, ***: P<0.001 vehicle vs bitter.
doi:10.1371/journal.pone.0145538.g006
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high-fat high-glucose diet [34]. The animals did, similarly to our experiment, not differ in
respiratory quotient, but total heat production was not reported in this study. In addition to
possible effects on adipocyte taste receptors, the involvement of other extra-oral taste receptors
in for example the gut or central nervous system cannot be excluded. It is also possible that a
change in skin thickness or composition might contribute to the observed changes [35]. Exam-
ples of genetically modified mice that were shown to have an increased heat production due to
an altered skin composition include mice deficient for stearoyl CoA desaturase 1 [36, 37] or
fatty acid elongase Elovl3 [38]. In these mice, a clear skin phenotype was reported, including
alopecia and a dry skin. α-gust-/- mice on the other hand did not show obvious phenotypic
changes in their skin or fur.
Surprisingly, α-gust-/- mice showed higher energy intake thanWT mice, despite having a
lower body weight. We speculate that this is a compensatory mechanism to adjust for the
increased energy expenditure. In contrast, the mRNA expression levels of hypothalamic neuro-
peptides are inconclusive with the observed difference in energy intake. The mRNA expression
levels of the orexigenic neuropeptides AgRP and NPY tended to be higher or were unchanged,
respectively, but also the expression of the anorexigenic neuropeptide POMC was upregulated.
Our results clearly indicate that the gustatory G-protein is involved in the induction of obe-
sity. As previous studies have shown that bitter taste receptors can regulate appetite by affecting
the release of (an)orexigenic gut hormones and by inhibiting gastric contractility we hypothe-
sized that activation of bitter taste receptors coupled to α-gustducin may represent a strategy to
prevent obesity. Mice were treated by oral gavage, to bypass effects of oral TAS2R stimulation
and to avoid the induction of aversive responses. Selecting bitter agonists to study in vivo
effects is challenging, firstly since bitter compounds are often toxic [39, 40], and secondly since
there are over 25 different TAS2Rs [41]. DB and quinine were selected because they can acti-
vate 8 and 9 different TAS2R subtypes, respectively [42], increasing the likelihood of targeting
at least one extra-oral TAS2R. Furthermore, both compounds are known to have a low toxicity
[43–46]. Quinine is being absorbed in the blood in mice after intragastric administration [47].
To our knowledge, it is unclear whether denatonium benzoate is being absorbed, however this
certainly is the case for benzoate [48].
WT but not α-gust-/- mice treated with DB or quinine showed a decreased body weight
gain, indicating that these effects involve the canonical taste-signaling pathway. Changes in
postprandial gut peptide levels do not seem to be responsible for the observed changes in body
weight after bitter treatment. Meal-induced plasma GLP-1 levels were increased modestly in
response to DB but not to quinine in an α-gustducin independent fashion. This indicates that
α-gustducin is not the main gustatory G-protein involved in DB-induced GLP-1 release but
Table 1. Relative mRNA expression levels of adipocyte differentiation markers in 3T3-F442A adipocytes after the 12-day differentiation period in
the presence of 150 μMDB, 100 μMQ or vehicle.
Differentiation
marker











Leptin 2.15±0.13 0.74±0.08 <0.001 0.0066±0.0017 <0.001
PPARγ 2.51±0.05 1.98±0.07 <0.01 2.02±0.06 <0.001
AP-2 1.73±0.28 1.44±017 >0.05 1.3±0.09 <0.01
FAS 1.07±0.11 0.91±0.07 <0.05 0. 8±0.15 <0.05
Adiponectin 3.05±0.14 2.44±0.11 <0.05 1.80±0.08 <0.001
UCP2 1.83±0.1 1.38±0.04 <0.01 1.07±0.09 <0.01
Pref-1 0.39±0.04 0.38±0.03 >0.05 0.41±0.05 >0.05
doi:10.1371/journal.pone.0145538.t001
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that also other taste-associated G-proteins such as transducin may be important [49]. Although
GLP-1 is an incretin hormone [50], there were no changes in post-meal plasma insulin or glu-
cose levels. One of the limitations of our study is that we could only measure peptide levels at
one time point and therefore possible time-dependent changes in meal-induced peptide release
cannot be excluded. Thus, although plasma GLP-1 levels peak 15 min after administration of
Nutridrink1, this time-point is too early to observe a postprandial decline in plasma ghrelin
levels [51]. Therefore the ghrelin that was measured rather represents plasma ghrelin levels
after a 6h fast which were not affected by long-term bitter treatment. Given that bitter agonists
are known to influence gut peptide release in vivo acutely, it remains possible that the observed
changes on body weight are the result of a summation of acute effects on gut peptide release
and changes in meal pattern [11, 13, 14]. In addition, recent studies showed that intragastric
administration of DB influences gastric motility both in mice and humans [19]. In humans, the
bitter-induced impaired fundic relaxation was associated with increased satiation during an
oral nutrient challenge test. Thus it is possible that a change in motility, also involved in appe-
tite generation, might be involved in the overall observed effects [52].
Bitter treatment did not induce major changes in food intake; DB-treatment decreased food
intake (mainly during the first week) in an α-gustducin dependent manner, while quinine did
not influence food intake at all during the four weeks of treatment. Correspondingly, hypotha-
lamic mRNA expression levels of the orexigenic neuropeptides AgRP and NPY were decreased
in DB-, but not water- or quinine-treated WTmice. The fact that gut peptides are not changed
drastically is suggestive for a direct effect of DB on the brain, since functional bitter taste recep-
tors for DB have been demonstrated in the brain [53].
Inhibition of body weight gain in lean mice in response to quinine treatment has previously
been reported by Cettour-Rose et al. [54]. However, in that study, a diet supplemented with
quinine was used, thus TAS2Rs in the oral cavity were not omitted. Nevertheless, correspond-
ing to our study, the effects of quinine on body weight were unrelated to changes in food intake.
The authors noted a decline in the inhibitory effect of quinine on weight gain in TRPM5-/-
mice, a cation channel crucial in taste transduction, further supporting the involvement of
taste signaling in the effects of bitter on body weight.
The body weight change observed in our study most likely resulted from a decrease in adi-
pose tissue mass. Therefore, we investigated whether DB and quinine could directly target adi-
pocytes. Our study shows for the first time that TAS2Rs are expressed in white adipose tissue
and 3T3-F442A cells. Indeed, the bitter agonists DB and quinine both inhibited 3T3-F442A
pre-adipocyte differentiation. Adding bitter compounds during the first 4 days of differentia-
tion did not affect adipocyte differentiation, while addition during the following 8 days did,
indicating that the bitter-induced effects are on adipocyte metabolism, rather than on adipo-
cyte differentiation. Future studies need to clarify whether the observed effects in vitro are
involved in the observations on body weight in vivo. Furthermore, it needs to be investigated
whether the bitter and sweet taste signaling pathways in adipose tissue might interact with each
other to regulate adipocyte function in response to nutrients, much like has been demonstrated
on the tongue [55] and in the nasal epithelium [56].
To conclude, chemosensory signaling of nutrients is an important factor in the development
of obesity, as mice that have a defective gustatory signaling pathway are less prone to develop
obesity. An increased heat production and elevated UCP1 protein indicate an increase in BAT
activity in mice lacking α-gustducin resulting in a decrease in WATmass and hence in lower
body weight gain. Furthermore, prolonged treatment of obese mice with DB or quinine
induced a reduction in body weight gain and WATmass that was α-gustducin dependent.
Food intake and gut peptide release were not strongly affected, while in vitro studies showed an
inhibitory effect of bitter treatment on adipocyte metabolism. The expression of TAS2R
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mRNA in WAT suggests the possibility of a direct effect of bitter agonists on adipocyte metab-
olism, which still has to be demonstrated in vivo. Therefore, targeting TAS2Rs might show
potential to influence adiposity and hence to treat obesity. However, future studies focusing
further on the effects of bitter agonists on adipose tissue, using tissue-specific knock-outs, are
warranted.
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P<0.05 water vs DB.
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obese WT and α-gust-/- mice. Plasma glucose levels in bitter treated WT (n = 9–12) and α-
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and 3T3-F442A cells. (a) RT-PCR transcripts coding for mTAS2R108 (DB and Q),
mTas2R135 (DB) and α-gustducin in obese WT mouse gonadal, subcutaneous and mesenteric
fat pads. (b) RT-PCR transcripts coding for mTas2R108, mTas2R135 and α-gustducin in
3T3-F442A cells. Samples in which no reverse transcriptase was added upon production of the
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